2023
DOI: 10.1186/s13024-023-00631-6
|View full text |Cite
|
Sign up to set email alerts
|

Optimizing detection of Alzheimer’s disease in mild cognitive impairment: a 4-year biomarker study of mild behavioral impairment in ADNI and MEMENTO

Abstract: Background Disease-modifying drug use necessitates better Alzheimer disease (AD) detection. Mild cognitive impairment (MCI) leverages cognitive decline to identify the risk group; similarly, mild behavioral impairment (MBI) leverages behavioral change. Adding MBI to MCI improves dementia prognostication over conventional approaches of incorporating neuropsychiatric symptoms (NPS). Here, to determine if adding MBI would better identify AD, we interrogated associations between MBI in MCI, and cer… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

0
9
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
7
1

Relationship

2
6

Authors

Journals

citations
Cited by 22 publications
(9 citation statements)
references
References 65 publications
0
9
0
Order By: Relevance
“…Longitudinally, MBI was associated with increasing p-tau, declining memory and executive function, and a 3.92-fold greater incidence rate of dementia (Ghahremani, Maryam et al, 2023). Similarly, in a study of MCI participants from ADNI and MEMENTO, MBI was associated with higher CSF p-tau levels at baseline, and increasing CSF p-tau levels over 4 years compared to the group with NPS not meeting MBI criteria (Ismail et al, 2023b). This finding was consistent in the ADNI test cohort (observational cohort) and in the MEMENTO validation cohort (memory clinic patients).…”
Section: Discussionmentioning
confidence: 91%
See 2 more Smart Citations
“…Longitudinally, MBI was associated with increasing p-tau, declining memory and executive function, and a 3.92-fold greater incidence rate of dementia (Ghahremani, Maryam et al, 2023). Similarly, in a study of MCI participants from ADNI and MEMENTO, MBI was associated with higher CSF p-tau levels at baseline, and increasing CSF p-tau levels over 4 years compared to the group with NPS not meeting MBI criteria (Ismail et al, 2023b). This finding was consistent in the ADNI test cohort (observational cohort) and in the MEMENTO validation cohort (memory clinic patients).…”
Section: Discussionmentioning
confidence: 91%
“…Several recent papers have demonstrated this point when MBI was compared to psychiatric disorders or NPS not meeting MBI criteria, with the MBI group having faster cognitive decline and progressing more rapidly to dementia (Ebrahim et al, 2023;Ghahremani, Maryam et al, 2023;Ismail et al, 2023a;Ismail et al, 2023b;Matsuoka et al, 2019;Taragano et al, 2018;Vellone et al, 2022), and even lower reversion rates from MCI to NC (McGirr, Alexander et al, 2022). For some, MBI is a proxy marker of underlying neurodegenerative disease pathology, associated with AD risk genes, amyloid, tau, and neurodegeneration (Andrews et al, 2018;Creese et al, 2021;Ghahremani, Maryam et al, 2023;Gill, S. et al, 2021;Ismail et al, 2023b;Johansson et al, 2021;Lussier et al, 2020;Matsuoka et al, 2023;Matsuoka et al, 2021;Matuskova et al, 2021;Miao et al, 2021a;Naude et al, 2020). Thus, a greater proportion of the MBI group has underlying AD compared to the conventional psychiatric/NPS group; this represents prodromal AD for MBI in MCI, and preclinical AD for MBI in NC.…”
Section: Introductionmentioning
confidence: 99%
See 1 more Smart Citation
“…Behavioral changes, also known as mild behavioral impairments (MBI), may be one of the early observable changes in AD and dementia [ 5 ]. MBI is associated with dementia biomarkers [ 6 ], and has been shown to be associated with cognitive impairment [ 7, 8 ] as well as risk of progression to dementia [ 9 ], and is a potential preclinical manifestation of underlying AD neuropathology [ 10 ]. In patients with SCD and MCI, MBI is characterized by neuropsychiatric symptoms (NPS)—“noncognitive behavioral and psychological symptoms of dementia” [ 11, 12 ].…”
Section: Introductionmentioning
confidence: 99%
“…The patient is unable to analyze, think and judge the events, and finds it difficult to deal with complex problems. Patients are unable to take care of themselves in daily life, making them and their family helpless over time (7,8). Although the exact process by which AD molecular cascades are triggered remains unclear, a series of epidemiological studies suggest that comorbid risk factors for metabolic disease are crucial in the pathogenesis of this disease (9)(10)(11).…”
Section: Introductionmentioning
confidence: 99%